Changing the pace of progress in lung cancer survival


We are the Lung Ambition Alliance

Lung cancer is the leading cause of cancer-related death. It claims a life every 18 seconds.1 40% are diagnosed after the disease has spread beyond the lung.2 Only one in five are alive five years after initial diagnosis.3

We’ve formed an alliance of the world’s top oncology minds to change the pace of progress in lung cancer survival.

Our ambition is to eliminate lung cancer as a cause of death.

The first step is to double five-year survival by 2025.



What is our approach?

We work together to accelerate advances and improve survival for people with lung cancer. We do this by advocating for improved approaches in three key areas:

INCREASED SCREENING RATES AND DIAGNOSTIC TESTING

We must increase early diagnosis and ensure the implementation of screening programs. We need to raise awareness of the strong evidence for screening, address other barriers to early detection and increase diagnostic accuracy.[4,5]

ACCELERATED DELIVERY OF INNOVATIVE MEDICINE

We must enable a paradigm-shift to earlier intervention, when potential for cure is greater, and place increased emphasis on early detection of relapse.[6,7] We believe precision medicine may be even more effective if utilized earlier in the course of the disease.[8] We are prioritizing the validation of surrogate endpoints which may enable better targeting of tumor characteristics and accelerate the development of new treatments.[9]

IMPROVED QUALITY CARE

We must urgently close the gap in cancer care quality urban centers and rural, community-based practices. We must also focus on addressing country-specific unmet needs. Additionally, as we progress against our ambitious survival goal, and lives extend, we must prioritize the development of programs and services which assist the growing population of survivors returning to everyday life.


We stand together

We are four distinct organizations, all with extensive and complementary experience in helping patients and healthcare professionals manage lung cancer.

We stand together to better understand how the disease evolves, develop advanced therapeutic techniques, and ultimately empower and enable patients to live longer and better lives.

 



We cannot do this alone

We need your support. We are asking for like-minded members of medical, scientific and advocacy communities to join us in pursuit of our ambition

 


Improve the quality of lung cancer care

The ILC2 program invites patient and caregiver organizations (registered as non-profit in their country) to submit proposals for initiatives with the potential to transform patient care.

 


References

  1. World Health Organization. International Agency for Research on Cancer. Fact Sheet – Lung Cancer. Available at http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed August 2019
  2. EpiCast Report: NSCLC Epidemiology Forecast to 2025. GlobalData. 2016.
  3. Cancer.Net. Lung Cancer - Non-Small Cell - Statistics. Available at www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Accessed May 2019
  4. Yousaf-Khan U, et al. Final Screening Round of the NELSON Lung Cancer Screening Trial: The Effect of a 2.5-year Screening Interval. Thorax. 2017;72:48–56.
  5. The National Lung Screening Trial Research Team. Reduced Lung-cancer Mortality with Low-dose Computed Tomographic Screening. N Engl J Med. 2011;365(5):395–409.
  6. Midthun D. Early detection of lung cancer. F1000Research. 2016;5(F1000 Faculty Rev):739
  7. NICE. The diagnosis and treatment of lung cancer (update). Available at https://www.ncbi.nlm.nih.gov/books/NBK99021/pdf/Bookshelf_NBK99021.pdf. Accessed August 2019
  8. Mathur S, et al. Personalised medicine could transform health care. Biomed Rep. 2017; (1) 3-5
  9. Jones G, et al. Recent advances in the management of lung cancer. Clinical Medicine. 2018;18(2):s41–s6
  10. Jemal a & Fedewa SA. Lung Cancer Screening With Low-Dose Computed Tomography in the United States—2010 to 2015. JAMA Oncol. 2017;3(9):1278-1281
  11. IASLC.org. IASLC Successfully Pilots Early Lung Imaging Confederation Project. Available at https://www.iaslc.org/news/iaslc-successfully-pilots-early-lung-imaging-confederation-project-0. Accessed August 2019
  12. Giroux, DJ et al. The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. Journal of Thoracic Oncology. 2018;13(6):801-809
  13. Jones G, et al. Recent advances in the management of lung cancer. Clinical Medicine. 2018;18(2):s41–s6
  14. Mascaux C, et al. Personalised medicine for nonsmall cell lung cancer. European Respiratory Review. 2017;26
  15. IASLC.org. IASLC Pathology Committee. Available at https://www.iaslc.org/research-education/iaslc-pathology-committee. Accessed August 2019